Substance use and substance use disorders (SUD) are well-known risk factors for elevated incidence of HIV, sexually transmitted infections (STIs) and Hepatitis C (HCV). Regular, accessible testing for HIV, STIs, and HCV is critical to controlling spread through early identification and prompt treatment. The array of treatment options for HIV and HCV has dramatically expanded with multiple regimens for each, many of which are curative for HCV. Pre-exposure prophylaxis (PrEP) is highly-effective for HIV prevention. In 2019, the U.S. designated 50 counties and cities as priority jurisdictions for intervention within the Ending the HIV Epidemic (EHE) initiative due to their high incidence of new infections. In this study, we utilized publicly available data to investigate availability of testing for HIV, STIs, and HCV and treatment for HIV, HCV, and PrEP for HIV prevention at over 5,000 substance use treatment facilities operating in the EHE priority jurisdictions. As frequent points of healthcare system contact for people with SUD, these treatment facilities present an opportunity to make meaningful progress in ending the HIV, STI, and HCV epidemics through expansion of testing and treatment services. This session presents data from the National Substance Use and Mental Health Services Survey (2023) conducted by the Substance Abuse and Mental Health Services Administration to present the current state of availability of testing and treatment services for HIV, HCV, and STIs. Specific opportunities for seamless integration of these services leveraging the existing care provided for SUD to integrate screening and treatment for viral and infectious diseases.